Crizotinib produces improved OS and PFS in EML4-ALK lung cancer... | Download Scientific Diagram
Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor–naive ALK + non−small cell lung cancer (ALTA-1L) - Lung Cancer
Response to Crizotinib Re-administration After Progression on Lorlatinib in a Patient With ALK-rearranged Non–small-cell Lung Cancer - Clinical Lung Cancer
Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial - Journal of Thoracic Oncology
Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK–Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls - ScienceDirect
Trials Highlight Changing Lung Cancer Treatment Landscape - NCI
Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression | BMC Cancer | Full Text
Crizotinib - Wikipedia
Phase III trial shows crizotinib superior to single-agent chemotherapy for ALK-positive advanced NSCLC | ESMO
Ensartinib
Pharmaceuticals | Free Full-Text | The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer | HTML
The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models | Nature Communications
Final OS analysis from the phase III j-alex study of alectinib (ALC) versus crizotinib (CRZ) in Japanese ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC) — ALK POSITIVE
Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification - Annals of Oncology
Brigatinib versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer | NEJM
Actionable Alterations - NSCLC Treatment Paradigm - Text Module - NSCLC Practical Guidance - Oncology - Clinical Care Options
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - Annals of Oncology
Phase III trial of crizotinib versus chemotherapy in previously treated... | Download Scientific Diagram
Alectinib Replaces Crizotinib Drug as Potential Therapy for Advanced Lung Cancer
Main adverse events with crizotinib in clinical trials | Download Table
First-Line ALK+ mNSCLC Clinical Trial - ALECENSA® (alectinib)
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial - The Lancet Oncology
Virtual clinical trial gives entrectinib edge over crizotinib against ROS1+ non-small cell lung cancer
The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC) | Molecular Cancer | Full Text
Post-Crizotinib Treatment ALK+ mNSCLC Clinical Trials - ALECENSA® (alectinib)
